Pacira BioSciences Inc (PCRX) 시세

Fully agree. I might add that global non Opioid pain treatment market size will be 140.56 b$ By 2031 of which Pacira has currently less than 1 b$ and it is (and will be more.and more) developing multiple products beyond Exparel so this is clearly an overreaction and the SP will recover a subsequent part of its losses.

This is a great opportunity to buy in.

PCRX 113% institution owned with 25% Float sold short Reminds me of SAVA

Buy some out of the money upside calls if there cheap

PCRX is Profitable huge revenues and growth

Income Statement
Revenue (ttm) 690.31M
Revenue Per Share (ttm) 14.88
Quarterly Revenue Growth (yoy) 5.00%
Gross Profit (ttm) N/A
EBITDA 175.34M
Net Income Avi to Common (ttm) 63.59M
Diluted EPS (ttm) 1.34

Company has over 400 Million in Cash

Book Value Per Share (mrq) 19.07 getting it for 11$ back down here all time lows for this stock with 113% institution ownership
Cash Flow Statement
Operating Cash Flow (ttm) 194.36M
Levered Free Cash Flow (ttm) 153.5M Cash flow positive

SAVA Dropped down to like 11$ then ran to 42$

PCRX over $20

PCRX still coming up from a bottom

wow, can you imagine if we will hit even just $1 because their revenue in 2019 is monstrous.

Wow this company only issued a small note and it doesnt exercise until Sept 2022, that if the holder will also exercise the notes because they have 18 months to do it. This is from their last 10-Q. This is imminent for a big run.

Penny land coming very very fast!

News: $PCRX Why Pacira BioSciences Is Soaring Today

Shares of Pacira BioSciences (NASDAQ: PCRX) are soaring on Monday and are up by 17.5% as of 12:10 p.m. EDT, and this despite the company not reporting any news. We can attribute Pacira's good fortune to one of its potential competitors in the market for postoperative pain, Heron Therapeutic...

Got this from PCRX - Why Pacira BioSciences Is Soaring Today

News: $PCRX Pacira BioSciences Reports First Quarter 2019 Revenues of $91.3 Million

-- EXPAREL® net product sales of $90.6 million up 22.4 percent over prior year first quarter -- -- MyoScience acquisition advances leadership in non-opioid pain management; corporate name change to Pacira BioSciences reflects expanding product portfolio -- -- Conference ...

Read the whole news https://marketwirenews.com/news-releases/pacira-biosciences-reports-first-quarter-2019-revenues-of-91-3-million-8100756.html

Buying a few puts here. I get skeptical of biotechs that run like this just a day before earnings. Also, not sure where they're at with integrating their acquisition earlier this year...and the impact on their financials. Will they take a charge? We'll see.

$PCRX

Pacira BioSciences shares are trading higher after competitor Heron Therapeutics' marketing application for a pain treatment was rejected by the FDA.
Benzinga

45.50 in pre market.

https://www.fda.gov/newsevents/newsroom/fdainbrief/ucm604021.htm

Partner Fund Management, L.P. has filed a new 13G, reporting 5.7% ownership in $PCRX - https://fintel.io/so/us/pcrx

PCRX bearish 36.42

$PCRX recent news/filings

bullish 72.42
moving average breakout
gap up
bullish divergence
high volume

## source: finance.yahoo.com

Tue, 15 Dec 2015 18:20:05 GMT ~ Pacira Pharma Soars on Settled FDA Case


read full: http://finance.yahoo.com/news/pacira-pharma-soars-settled-fda-182005335.html
*********************************************************

Tue, 15 Dec 2015 17:34:00 GMT ~ Pacira Pharmaceuticals (PCRX) Stock Surges After Regulators Resolve Free Speech Dispute


read full: http://www.thestreet.com/story/13398452/1/pacira-pharmaceuticals-pcrx-stock-surges-after-regulators-resolve-free-speech-dispute.html?puc=yahoo&cm_ven=YAHOO
*********************************************************

Tue, 15 Dec 2015 16:33:00 GMT ~ Skyepharma skips on Pacira's Exparel agreement with FDA


read full: http://uk.finance.yahoo.com/news/skyepharma-skips-paciras-exparel-agreement-163300512.html
*********************************************************

Tue, 15 Dec 2015 16:32:56 GMT ~ Pacira Pharma shares jump after FDA drops drug restriction


read full: http://sg.finance.yahoo.com/news/pacira-pharma-shares-jump-fda-163256877.html
*********************************************************

Tue, 15 Dec 2015 16:32:56 GMT ~ Pacira Pharma shares jump after FDA drops drug restriction


read full: http://finance.yahoo.com/news/pacira-pharma-shares-jump-fda-163256253.html
*********************************************************

$PCRX charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$PCRX company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/PCRX/company-info
Ticker: $PCRX
OTC Market Place: Not Available
CIK code: not found
Company name: Pacira Pharmaceuticals, Inc.
Incorporated In:

Business Description:

$PCRX share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$PCRX extra dd links

Company name: Pacira Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=PCRX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=PCRX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=PCRX+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/PCRX/news - http://finance.yahoo.com/q/h?s=PCRX+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/PCRX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/PCRX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=PCRX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/PCRX
DTCC (dtcc.com): http://search2.dtcc.com/?q=Pacira+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Pacira+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Pacira+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/PCRX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/PCRX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/PCRX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=PCRX&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=PCRX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/PCRX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=PCRX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=PCRX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=PCRX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=PCRX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=PCRX+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/PCRX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=PCRX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/PCRX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=PCRX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/PCRX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/PCRX/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/PCRX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/PCRX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/PCRX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=PCRX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=PCRX



$PCRX DD Notes ~ http://www.ddnotesmaker.com/PCRX

Looks good. if it was going to drop it would have done so already. This wants to go some more. jumped in today!

Anyone else think this has the potential to bounce back? Its currently oversold at 68.81 and started to rise after market hours. Could be potential profit right here!

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=106596431&txt2find=PCRX

http://seekingalpha.com/news/2081095-more-on-pacira-pharmaceuticals-q3-results

$PCRX Brean Capital Maintains Buy On Pacira Following Visit In Manufacturing Site http://www.smarteranalyst.com/2014/10/08/brean-capital-maintains-buy-on-pacira-following-visit-in-manufacturing-site/

Wedbush Reiterates Outperform On Pacira Following Stronger-Than-Expected July Estimates For EXPAREL http://www.smarteranalyst.com/2014/08/21/wedbush-reiterates-outperform-on-pacira-following-stronger-than-expected-july-estimates-for-exparel/

Pacira Pharmaceuticals, Inc. [$PCRX] due diligence

bullish

$PCRX

DD Notes ~ http://www.ddnotesmaker.com/PCRX

##### recent news/filings ~ source: finance.yahoo.com

Fri, 27 Jun 2014 14:30:15 GMT ~ Pacira's Exparel Positive in Phase IV Studies
read full: http://finance.yahoo.com/news/paciras-exparel-positive-phase-iv-143015179.html
*********************************************************

Fri, 27 Jun 2014 11:56:55 GMT ~ Coverage initiated on Pacira Pharma by Canaccord Genuity
read full: http://finance.yahoo.com/q/ud?s=PCRX
*********************************************************

Thu, 26 Jun 2014 10:31:00 GMT ~ 6:31 am Pacira Pharma announces publication of pooled results from IMPROVE studies evaluating health economic benefits of EXPAREL; EXPAREL-based multimodal regimen was associated with significant reductions in opioid consumption, incidence
read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#pcrx
*********************************************************

Thu, 26 Jun 2014 10:30:00 GMT ~ Pacira Pharmaceuticals, Inc. Announces Publication of Pooled Results from IMPROVE Studies Evaluating Health Economic Benefits of EXPAREL®
[Business Wire] - Pacira Pharmaceuticals, Inc. today announced results from a pooled analysis of IMPROVE, a series of open-label prospective, Phase 4 clinical studies designed to compare postsurgical narcotic use and health economic outcomes associated with EXPAREL® as the foundation of a multimodal analgesic regimen versus a standard opioid-based pain management regimen.
read full: http://finance.yahoo.com/news/pacira-pharmaceuticals-inc-announces-publication-103000008.html
*********************************************************

Thu, 19 Jun 2014 13:45:00 GMT ~ Pacira Pharmaceuticals (PCRX) Reaches New Lifetime High Today
read full: http://www.thestreet.com/story/12750236/1/pacira-pharmaceuticals-pcrx-reaches-new-lifetime-high-today.html?puc=yahoo&cm_ven=YAHOO
*********************************************************

##### chart ~ source: stockcharts.com



##### chart ~ source: eoddata.com



##### company info ~ source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/PCRX/company-info
Ticker: $PCRX
OTC Market Place: Not Available
CIK code: not found
Company name: Pacira Pharmaceuticals, Inc.
Incorporated In:

##### extra dd links

Latest filings: http://www.otcmarkets.com/stock/PCRX/filings
Latest financials: http://www.otcmarkets.com/stock/PCRX/financials
Latest news: http://www.otcmarkets.com/stock/PCRX/news - http://finance.yahoo.com/q/h?s=PCRX+Headlines

Major holdings: http://data.cnbc.com/quotes/PCRX/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=PCRX+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/PCRX.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=PCRX

RegSho: http://www.regsho.com/tools/symbol_stats.php?sym=PCRX&search=search

DTCC: http://search2.dtcc.com/?q=Pacira+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&q=Pacira+Pharmaceuticals%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results?term=Pacira+Pharmaceuticals%2C+Inc.&x=0&y=0

Short Sales: http://www.otcmarkets.com/stock/PCRX/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/PCRX/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/PCRX/research
Historical Prices: http://finance.yahoo.com/q/hp?s=PCRX+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=PCRX+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=PCRX+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=PCRX+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=PCRX+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=PCRX+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=PCRX
Balance Sheet: http://finance.yahoo.com/q/bs?s=PCRX
Cash Flow: http://finance.yahoo.com/q/cf?s=PCRX+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/PCRX
Bloomberg: http://www.bloomberg.com/quote/PCRX:US
Morningstar: http://quotes.morningstar.com/stock/s?t=PCRX
Bussinessweek: http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=PCRX
Barchart: http://www.barchart.com/quotes/stocks/PCRX
OTC Short Report: http://otcshortreport.com/index.php?index=PCRX
Investopedia: http://www.investopedia.com/markets/stocks/PCRX/?wa=0

http://www.pennystocktweets.com/stocks/profile/PCRX

##### last known share structure ~ source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

##### business description ~ source: otcmarkets.com



DD Notes ~ http://www.ddnotesmaker.com/PCRX
xlfv

high market cap for hi valued companies. other as blue chips pacira won't get dumped in the coming correction impo. sry for late reply but I'm rarely on boards. well, I bought long before earnings....

Pretty high market cap here, but product is great and I suspect financials tomorrow will be positive. Thoughts on buying now prior to financials or waiting to watch price action after announcement. Thx

+28% since my last call 40d ago and Pacira is still movin'

next leg UP from the IMPROVE study in laparoscopic colectomy. IMPROVE represents a series of open-label prospective Phase 4 clinical studies to assess the differences in postsurgical opioid use and health economic outcomes between patients receiving EXPAREL® (bupivacaine liposome injectable suspension) as the foundation of a multimodal analgesic regimen versus a standard opioid-based regimen for postsurgical pain control. The results were published in the January issue of Current Therapeutic Research.

4:30PM Pacira Pharma: Phase 4 IMPROVE publication fids EXPAREL-based multimodal analgesia reduces opioid use, adverse events and hospital stay following laparoscopic surgery (PCRX) 57.26 +1.43 : Co announced results from the IMPROVE study in laparoscopic colectomy. IMPROVE represents a series of open-label prospective Phase 4 clinical studies to assess the differences in postsurgical opioid use and health economic outcomes between patients receiving EXPAREL (bupivacaine liposome injectable suspension) as the foundation of a multimodal analgesic regimen versus a standard opioid-based regimen for postsurgical pain control. The results were published in the January issue of Current Therapeutic Research.

The study evaluated 82 patients who underwent laparoscopic colectomy, a minimally invasive surgery to remove all or part of the colon using several small incisions in the abdomen. Compared to patients in the standard opioid-based treatment arm-who received intravenous (IV) opioids via patient-controlled analgesia (PCA) devices-patients undergoing the same procedure and receiving an EXPAREL-based multimodal regimen experienced:

A 64 mg reduction in mean opioid consumption (32 mg in the EXPAREL group compared with 96 mg in the IV opioid-based PCA group; P<0.0001)
A 1-day reduction in median length of hospital stay (3.0 days in the EXPAREL group compared with 4.0 days in the IV opioid-based PCA group; P=0.0019)
Significantly fewer opioid-related adverse events (ORAEs) (8 percent of patients in the EXPAREL group experienced ORAEs, compared with 41 percent of patients in the IV opioid-based PCA group; P=0.0019)
A $1,784 reduction in mean hospitalization costs ($11,234 in the EXPAREL group compared with $13,018 in the IV opioid-based PCA group)

4:33PM Pacira Pharma: Study shows EXPAREL provided improved pain control, shorter length of hospital stay and substantial cost savings following total knee replacement (PCRX) 40.97 +0.16 : Co announced results from a 200-patient study evaluating the benefits of EXPAREL (bupivacaine liposome injectable suspension) as the foundation of a multimodal postsurgical pain management regimen in patients undergoing total knee arthroplasty (TKA), commonly known as total knee replacement. The findings show that patients treated with EXPAREL experienced better pain control with improved knee flexion and a shorter length of hospital stay compared to patients who received a femoral nerve block with a local anesthetic, the current standard of pain management for TKA. Additionally, the use of EXPAREL resulted in a substantial cost savings.

8:47AM Pacira Pharma Correction: PCRX was NOT downgraded by Barclays on Friday, firm maintained Overweight and $40 tgt; prior comment has been removed (PCRX) : Correction: PCRX was NOT downgraded by Barclays on Friday, firm maintained their Overweight and $40 tgt; prior comment has been removed.

6:32AM Pacira Pharma announces positive interim analysis of EXPAREL in femoral nerve block for total knee arthroplasty (PCRX) 29.62 : Co announced findings from the completed first part of its Phase 2/3 clinical trial assessing the use and administration of EXPAREL (bupivacaine liposome injectable suspension) as a single-dose injection femoral nerve block for total knee arthroplasty surgery (TKA). Results show safety and efficacy of EXPAREL in femoral nerve block to support initiation of the Phase 3 portion of the pivotal trial. Based on the evaluation of both safety and efficacy after 72 hours of follow-up, a single dose level was to be selected for assessment in the second part of the study. Following the review of the data, the committee responsible for assessing the safety and efficacy profile determined that EXPAREL should be dosed at 266 mg in the Phase 3 portion of the study, which will be initiated shortly. The committee also confirmed that if results from the Phase 2 portion of the trial are replicated in Phase 3, the target enrollment of 180 patients should be adequate to demonstrate the safety and efficacy of the indication.

In addition, co also reported that patient enrollment was completed in a second Phase 3 nerve block clinical trial. This double-blind, placebo-controlled intercostal nerve block study enrolled 180 patients (90 patients on each arm) who were undergoing thoracotomy. The co expects that results from this additional Phase 3 study will contribute to a planned FDA supplemental New Drug Application (sNDA) submission anticipated for early 2014.

New Published Analysis Finds Opioid-Related Adverse Events Increase Hospital Stays, Costs of Care and Risks of Readmission and Mortality
Retrospective Study Published in Pharmacotherapy Identifies Advanced Age, Obesity, Pre-Surgery Opioid Use and Comorbid Conditions as Predictive Risk Factors for Adverse Events
Press Release: Pacira Pharmaceuticals, Inc. – 3 hours ago

PARSIPPANY, N.J.--(BUSINESS WIRE)--
Pacira Pharmaceuticals, Inc. (PCRX) today announced the publication of findings from a retrospective analysis of more than 37,000 patients who underwent common inpatient surgeries at a large, 26-hospital healthcare system and received opioids for postsurgical pain management. According to the data, published in this month’s issue of Pharmacotherapy, patients who experienced opioid-related adverse events (ORAEs) had statistically significantly higher hospital costs, longer hospital stays and increased risks of readmission and mortality.
Specifically, patients experiencing an ORAE:
Had a 55 percent longer hospital stay than patients without an ORAE (9.5 days vs. 6.1 days, P
Had a 47 percent higher hospitalization cost compared to patients without an ORAE ($21,012 vs. $14,291, P
Had a 36 percent increased risk of 30-day readmission compared to patients without an ORAE (P
Had a 3.4 times greater risk of inpatient mortality than patients without an ORAE (P
Researchers were also able to identify a series of characteristics that increased patients’ risks for ORAEs. Predictive risk factors for an adverse event related to opioid use included: patient age of 65 or older, obesity, greater number of comorbidities and pre-surgery opioid use.
“This regionally focused analysis mirrors findings from previously published national analyses that demonstrated the meaningful and measurable impact of opioid-related adverse events on patient outcomes and healthcare system costs,” said Dave Stack, President and CEO of Pacira Pharmaceuticals, Inc. “While opioids have long been the mainstay of postsurgical pain management, a recent groundswell of advocacy to mitigate potentially fatal side effects may drive a shift in the current postsurgical pain management paradigm toward non-opioid or opioid-sparing pain regimens, especially in high-risk patients.”
In this retrospective analysis, researchers reviewed administrative discharge data at 26 hospitals in the southeastern United States, and identified 37,031 adult patients who underwent common soft tissue and orthopedic surgical procedures from January 2009 to December 2010. Among this patient sample, 98.6 percent received opioids after surgery, and 13.6 percent of those received a diagnosis of respiratory, gastrointestinal, central nervous system, urinary or other opioid-related adverse events during hospitalization.
Researchers conducted statistical analysis to evaluate risk factors that may predispose patients to postsurgical ORAEs and compared differences in length of stay, total hospitalization costs, 30-day readmission rates and inpatient mortality between the patients who experienced an ORAE and those who did not.
The research was supported by Pacira Pharmaceuticals, Inc. The full publication is available online here.

6:30AM Pacira Pharma announces new data support the benefits of EXPAREL for postsurgical analgesia following aesthetic plastic surgery procedures (PCRX) 29.30 : Co announced results from EXCLAIM, its Phase 4 prospective, observational study to assess the use of EXPAREL (bupivacaine liposome injectable suspension) for postsurgical analgesia in patients undergoing four common plastic surgery procedures. Patients who received EXPAREL following abdominoplasty, breast augmentation, breast reduction or a combination abdominoplasty/breast procedure reported low pain scores, high satisfaction with pain control and minimal opioid use. Key findings demonstrated that patients treated with EXPAREL reported:

Low pain scores (mean score of =4.0 on pain intensity scale of 0-10)
Minimal opioid use for rescue pain relief (mean of <3 tablets taken daily vs historically expected 10 tablets per day in a typical postsurgical pain management paradigm)
High satisfaction with pain management (all patients reported =3.0 on a 0-4 scale)
Excellent overall benefit of analgesia (OBAS) achieved with EXPAREL (mean score of =5 out of a possible 28 points)

6:45AM Pacira Pharma: Analysis of postsurgical pain management finds opioid-related adverse events drive longer hospital stays, greater cost and higher likelihood of readmission (PCRX) 28.69 : Co announced data from a large-scale analysis of a national database of patients from 380 hospitals in the United States who underwent 319,898 inpatient surgeries and received opioids for postsurgical pain management. The analysis found that opioid-related adverse events were associated with a $4,707 increase in hospital costs and a 3.3-day increase in the average length of stay in the hospital. The data were published in this month's issue of the Journal of Pain and Palliative Care Pharmacotherapy.

Pacira Pharmaceuticals' CEO Discusses Q4 2012 Results - Earnings Call Transcript

http://seekingalpha.com/article/1256011-pacira-pharmaceuticals-ceo-discusses-q4-2012-results-earnings-call-transcript?source=yahoo

http://www.secform4.com/insider-trading/1396814.htm

What do you think? $20 possible?

6:31AM Pacira Pharma: New data demonstrate reduction in opioid use, hospital cost and length of stay with EXPAREL as the foundation of a multimodal regimen (PCRX) 15.78 : Co announced that results from the first IMPROVE study to complete its prospective Phase 4 clinical program were published in the online version of the Journal of Pain Research. The IMPROVE studies compare the difference in opioid use, total hospital cost and length of stay (LOS) between patients receiving EXPAREL (bupivacaine liposome injectable suspension) as the foundation of an opioid-sparing multimodal regimen versus a standard opioid-based postsurgical pain management regimen. Compared to patients undergoing open colectomy in the standard opioid-based treatment arm, patients undergoing the same procedure and receiving an EXPAREL-based multimodal regimen had: A 2.9-day reduction in median LOS (4.9 days in the hospital vs 2.0 days in the hospital, respectively; P=0.004); A $3,084 reduction in mean total hospital cost ($11,850 vs $8,766, respectively; P=0.027); A 58 mg reduction in mean opioid consumption (115 mg vs 57 mg, respectively; P=0.025). The overall safety profile for EXPAREL was consistent with previous experiences in the Phase 3 program.

6:31AM Pacira Pharma announced new data supporting use of EXPAREL via Infiltration into the Transversus Abdominis Plane; 100% of the available subjects reported being either satisfied or extremely satisfied with their postsurgical pain control (PCRX) 15.89 : Twenty-four patients undergoing robotic prostatectomy were enrolled in this open-label, prospective study to evaluate the efficacy and safety of EXPAREL via TAP infiltration. Key findings include:

Patients required a mean of less than one oxycodone/acetaminophen tablet per day from their discharge until their day 10 visit.
100 percent of the available subjects reported being either satisfied or extremely satisfied with their postsurgical pain control at hospital discharge, at 72 hours and on day 10.
When retrospectively compared to a 2011 study of patients who received a TAP infiltration of bupivacaine HCl, patients administered EXPAREL in the same fashion had similar or better pain scores with a reduced requirement for opioids.
There were no treatment-related adverse events in the study.
EXPAREL is indicated for single-dose administration into the surgical site to produce postsurgical analgesia.

6:32AM Pacira Pharma EXPAREL, as the foundation of a multimodal regimen, achieves statistical significance in all primary endpoints, including a 60% reduction in length of hospital stay (PCRX) 18.55 : Co announces topline results from the first completed IMPROVE study in its prospective Phase 4 clinical program. The study was designed to compare the difference in three primary endpoints, cost, opioid consumption and hospital length of stay, between one group of patients receiving a standard opioid-based postsurgical pain management regimen and a second group of patients receiving EXPAREL as the foundation of an opioid-sparing multimodal regimen. The EXPAREL-based multimodal regimen achieved a statistically significant reduction in each primary endpoint, including a 60% reduction in LOS in patients undergoing open colectomy, a surgical procedure to remove all or part of the colon through an incision in the abdominal wall. EXPAREL is a non-opioid local analgesic indicated for administration into the surgical site to produce postsurgical analgesia. The overall safety profile for EXPAREL was consistent with previous experiences in the Phase 3 program.

Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2012 Financial Results Webcast and Conference Call
Press Release: Pacira Pharmaceuticals, Inc. – Tue, Jul 31, 2012 6:30 AM EDT.. .

PARSIPPANY, N.J.--(BUSINESS WIRE)--

Pacira Pharmaceuticals, Inc. (PCRX) today announced that financial results for the company's second quarter ended June 30, 2012, will be released before the market opens on Thursday, August 9, 2012. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Thursday, August 9, 2012, at 9 a.m. ET. The call can be accessed by dialing 1-866-770-7120 (domestic) or 1-617-213-8065 (international) five minutes prior to the start of the call and providing the passcode 32008208.

A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), and providing the passcode 95762478. The replay of the call will be available for two weeks from the date of the live call.

The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the company's website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the call.

About Pacira

Pacira Pharmaceuticals, Inc. (PCRX) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, EXPAREL® (bupivacaine liposome injectable suspension), was commercially launched in the United States in April 2012. EXPAREL and two other commercially available products utilize the Pacira proprietary product delivery technology DepoFoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.

Contact:.
.
Pacira Pharmaceuticals, Inc.
James S. Scibetta, Chief Financial Officer
973-254-3570

Pacira Pharmaceuticals (PCRX) has been selected for inclusion in the NASDAQ Biotechnology Index effective today.

6:52AM Pacira Pharma misses by $0.07; beats on revs (PCRX) 10.56 : Reports Q1 net loss of $0.47 vs ($0.40) CIQ est; revs increased 100% to $7.8 mln vs $7.5 mln CIQ est. Co ended the first quarter of 2012 with cash and cash equivalents, restricted cash and short-term investments of $54.8 mln.

6:30AM Pacira Pharma completes $27.5 mln debt refinancing (PCRX) 11.00 : Co announced that it has secured a $27.5 million debt financing facility through Oxford Finance. Pacira will use the proceeds from this financing to refinance the remaining principal of its outstanding term loan and for general corporate purposes. The refinancing allows Pacira to defer the first monthly payment of principal until December 1, 2013. In addition, the refinancing was achieved at a lower interest rate compared to the existing term loan rate and the interest rate is fixed, eliminating any future interest rate risk. The facility includes an interest rate of 9.75% and requires monthly interest-only payments until December 2013, followed by a 30-month principal amortization period. In addition, Oxford Finance will receive warrants to purchase an aggregate of 162,885 shares of Pacira common stock at an exercise price of $10.97.

Pacira Pharma prices 6 mln share common stock offering at $9.75/share (PCRX) 10.12 :

7:27AM On The Wires (WIRES) : Pacira Pharmaceuticals (PCRX) announced the commercial launch of EXPAREL in the U.S.

~ Monday! $PCRX ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $PCRX ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=PCRX&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=PCRX&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=PCRX
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=PCRX#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=PCRX+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=PCRX
Finviz: http://finviz.com/quote.ashx?t=PCRX
~ BusyStock: http://busystock.com/i.php?s=PCRX&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=PCRX >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

Pacira Pharmaceuticals, Inc. Provides Update on Commercial Launch and Product Availability Timing for EXPAREL®

EXPAREL Expected to be Commercially Available in April 2012
Business WirePress Release: Pacira Pharmaceuticals, Inc. – Mon, Jan 9, 2012 6:30 AM EST

PARSIPPANY, N.J.--(BUSINESS WIRE)-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX - News) today provided updated timing for its commercial launch of EXPAREL® (bupivacaine liposome injectable suspension), a non-opioid analgesic that was approved by the U.S. Food and Drug Administration (FDA) for administration into the surgical site to produce postsurgical analgesia.

Since FDA approval of EXPAREL in October 2011, Pacira has continued to execute its pre-commercial launch strategy focused on the broad hospital market and has undertaken initiatives to expand and enhance its ability to efficiently manufacture commercial quantities of EXPAREL.

As planned, Pacira has hired and trained a sales force and will proceed with a formulary-access driven launch strategy, beginning with a national sales meeting this week. Due to commercial manufacturing challenges, which Pacira is confident it can address, the company projects product availability in April 2012, by which time Pacira expects it will have manufactured sufficient product to meet customer demands at launch.

“Our goal is to ensure that we have an appropriate commercial supply of EXPAREL to support anticipated demand for the product following our launch,” said Dave Stack, president and chief executive officer of Pacira. “We are encouraged by the positive response we have received following FDA approval of EXPAREL and our organization is focused on our commercial manufacturing processes. With the recent appointment of John Pratt to the newly created role of general manager for our San Diego manufacturing facility, we believe we have added leadership who will directly contribute to our ability to meet our goals. John has more than 35 years of experience in building and leading state-of-the art pharmaceutical manufacturing and quality control organizations including senior positions at Amylin and Novo Nordisk, and his expertise will be valuable as we execute our manufacturing strategy. We are very excited about EXPAREL and the role it can play in optimizing postsurgical pain management and look forward to bringing this product to the market.”

Taunia Markvicka, vice president, commercial at Pacira, added, “During the first quarter our sales force will work closely with our commercial and scientific affairs teams to achieve formulary approvals at our target hospitals. In line with our announced strategy, we have introduced multiple important educational initiatives, including preceptorship programs, and continued to work to implement opioid sparing protocols within several key institutions. We are also initiating our Phase 4 clinical programs that will provide healthcare professionals with hands-on experiences with the product. We believe all of these activities will help drive additional demand for EXPAREL as we continue to focus our promotional programs and investments to align the deployment of our resources with near-term revenue opportunities.”

Pacira Pharma announces pricing of follow-on offering at $6.50/share (PCRX) 6.87 : Co announced the pricing of its public offering of 7 mln shares of its common stock at a price of $6.50 per share. All of the 7 mln shares are newly issued and are being offered by Pacira, with expected net proceeds to Pacira of ~$42.3 mln after deducting underwriting discounts and commissions and estimated offering expenses.

This board has completely calmed up. What does that tell investors that bought at 11. Can you smell manipulation?

Someone said $15 after approval.
Someone said maybe $20.


PCRX is at $7.00 now.

It's no wonder people have a dime view of the markets.


Cheers!

The three day chart isn't looking too good for PCRX.
Think I'll wait for sub 7.